Drug Profile

SAL 0120

Alternative Names: SAL-0120

Latest Information Update: 28 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shenzhen Salubris Pharmaceuticals
Class Antihypertensives; Small molecules; Urologics
Mechanism of Action Endothelin A receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Hypertension; Renal failure

Most Recent Events

20 Mar 2026 Pharmacodynamics data from a preclinical studies in Renal failure released by Shenzhen Salubris Pharmaceuticals
18 Mar 2026 Shenzhen Salubris Pharmaceuticals to advance SAL 0120 to phase III clinical trial in patients with CKD in 2026
09 Jan 2026 Shenzhen Salubris Pharmaceuticals completes phase-I clinical trials in Hypertension (In volunteers) in China (PO) (CTR20254965)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com